Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»Northwestern Medicine Launches COVID-19 Drug Trial
    Health

    Northwestern Medicine Launches COVID-19 Drug Trial

    By Northwestern UniversityApril 4, 20202 Comments3 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email Reddit
    Remdesivir COVID-19 Coronavirus
    Remdesivir, developed for Ebola, shows antiviral activity against coronaviruses including MERS and SARS-Cov-2.

    Remdesivir was developed for Ebola and has antiviral activity for coronaviruses.

    Northwestern Medicine has enrolled its first participants in a new international clinical drug trial for COVID-19. The drug being tested is remdesivir, a novel anti-viral drug developed to treat Ebola and which has subsequently been found, in animal models, to have antiviral activity against coronaviruses including MERS and now SARS-Cov-2, the virus that causes COVID-19 disease.

    The randomized, placebo-controlled, double-blind trial will evaluate the safety and efficacy of the drug in hospitalized adult patients diagnosed with COVID-19.

    The first Chicago-area patient to enroll in the trial at Northwestern Medicine is an 89-year-old man in intensive care. “His family was very excited about it,” said principal investigator Dr. Babafemi Taiwo, chief of infectious diseases at Northwestern University Feinberg School of Medicine and Northwestern Medicine.

    “I think it’s fantastic this trial is off the ground,” Taiwo said. “It puts something in our hands that we can investigate in a rigorous fashion in the quest for therapies that may be effective and widely adopted to treat the pandemic.“

    Before the clinical trial, remdesivir was used to treat a handful of patients on a compassionate access program basis. “It’s too early to say if there is an effect because some of them are still receiving the treatment,” Taiwo said.

    Participants in the trial receive either a placebo drug or remdesivir intravenously once a day for a maximum of 10 days. If a patient recovers sooner, the treatment is stopped. The patient will be evaluated for 30 days. About 50 sites around the country will enroll 440 patients in the trial.

    While the study will last three years, the results may come in sooner. “I think we’ll get our results soon because the enrollment pace is very quick,” Taiwo said. “I hope that in a matter of months, we’ll be able to tell whether this therapy is effective or not.”

    In four studies of healthy people and participants in Ebola trials in Africa, the drug led to elevation of liver function test in some recipients, meaning the liver has to be carefully monitored. This effect was transient. Other participants had some abnormality in blood clotting tests and gastrointestinal side effects. None of these were serious.

    The trial is sponsored by the National Institute of Allergy and Infectious Diseases/Division of Microbiology and Infectious Diseases of the National Institutes of Health.

    Reference: “Adaptive COVID-19 Treatment Trial (ACTT)” sponsored by National Institute of Allergy and Infectious Diseases (NIAID), 21 February 2020.
    NCT: NCT04280705

    Never miss a breakthrough: Join the SciTechDaily newsletter.
    Follow us on Google and Google News.

    COVID-19 Microbiology National Institutes of Health Northwestern University Virology
    Share. Facebook Twitter Pinterest LinkedIn Email Reddit

    Related Articles

    Promising MERS Vaccine Candidate Might Be Able to Block Coronavirus Infections

    Coronavirus Fight: Scientists Identify COVID-19 Drug That “Kills” the Virus Within 48 Hours

    New Coronavirus That Causes COVID-19 Is Stable for Hours on Surfaces

    Targets for Vaccines and Treatments Revealed by Novel Coronavirus Structure

    COVID-19: A Potent Reminder of the Challenge of Emerging Infectious Diseases

    Clinical Trial of Antiviral Remdesivir to Treat COVID-19 Underway

    Breakthrough in Coronavirus Vaccine Research Results in New 3D Atomic Scale Map of Virus

    Strains of Coronavirus 2019-nCoV Detected in France Isolated

    Research Underway to Address Threat of Novel Coronavirus That Recently Emerged in China

    2 Comments

    1. Swati Chandran on April 7, 2020 7:45 am

      In the middle of this difficult situation, this looks like a real HOPE.
      Need to save the world.

      Reply
    2. Swati Chandran on April 7, 2020 7:46 am

      In the middle of this difficult situation, this looks like real HOPE.
      Need to save the world.

      Reply
    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    NASA’s Voyager 1 Is About to Become the First Spacecraft One Light-Day From Earth

    A Woman Who Lived 30,000 Years Ago Is Changing What We Know About Ice Age Europe

    A Rare Radioactive Element Reveals a Hidden Secret About the Heaviest Atoms

    Breakthrough Cancer Treatment Wipes Out Deadly Brain Tumors in Every Mouse Tested

    Something Remarkable Is Happening to Dogs Living Near Chernobyl’s Nuclear Plant

    Hubble Uncovers a Mysterious 93-Billion-Mile Structure Hiding in a Nearby Star System

    Earth’s Oceans Were Slowly Suffocating Millions of Years Before a Devastating Mass Extinction

    Why Are Men Twice As Likely To Develop Parkinson’s? Scientists Discover a Hidden Clue in the Brain

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • Scientists Find That Older Brains React Very Differently to a Night of Poor Sleep
    • A Hidden Substance in Drinking Water May Be Linked to Heart Problems in Children
    • Scientists Find a Clever Way to Read Quantum Information Without Destroying It
    • Chemical Breakthrough Could Unlock the “Holy Grail” of Solid-State Battery Technology
    • Kids Who Learn To Swim Early May Have an Unexpected Advantage in School
    Copyright © 1998 - 2026 SciTechDaily. All Rights Reserved.
    • Science News
    • About
    • Contact
    • Editorial Board
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.